29 related articles for article (PubMed ID: 25459258)
1. Surgical wound dehiscence complicated by methicillin-resistant
Zardi EM; Montelione N; Vigliotti RC; Chello C; Zardi DM; Spinelli F; Stilo F
Clin Med (Lond); 2020 Jan; 20(1):98-100. PubMed ID: 31941740
[TBL] [Abstract][Full Text] [Related]
2. EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma.
Hovinga KE; McCrea HJ; Brennan C; Huse J; Zheng J; Esquenazi Y; Panageas KS; Tabar V
J Neurooncol; 2019 Apr; 142(2):337-345. PubMed ID: 30680510
[TBL] [Abstract][Full Text] [Related]
3. Management of a complex scalp defect.
Plast Reconstr Surg; 2008 Aug; 122(2):623-625. PubMed ID: 18626384
[No Abstract] [Full Text] [Related]
4. Discussion: Management of a complex scalp defect.
Serletti JM
Plast Reconstr Surg; 2008 Aug; 122(2):626-629. PubMed ID: 18626385
[No Abstract] [Full Text] [Related]
5. Impact of bevacizumab chemotherapy on craniotomy wound healing.
Clark AJ; Butowski NA; Chang SM; Prados MD; Clarke J; Polley MY; Sughrue ME; McDermott MW; Parsa AT; Berger MS; Aghi MK
J Neurosurg; 2011 Jun; 114(6):1609-16. PubMed ID: 21142749
[TBL] [Abstract][Full Text] [Related]
6. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY
Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555
[TBL] [Abstract][Full Text] [Related]
7. Case report of interstitial nephritis induced by bevacizumab therapy for glioblastoma multiforme.
Lomax AJ; Hill PA; Ashley DM
J Oncol Pharm Pract; 2013 Dec; 19(4):365-8. PubMed ID: 23235917
[TBL] [Abstract][Full Text] [Related]
8. Extremely late wound dehiscence following bevazicumab treatment in a long term survival glioblastoma patient.
Laviv Y; Rappaport ZH
Clin Neurol Neurosurg; 2014 Dec; 127():125-7. PubMed ID: 25459258
[No Abstract] [Full Text] [Related]
9. Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.
Narita Y
Jpn J Clin Oncol; 2013 Jun; 43(6):587-95. PubMed ID: 23585688
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.
Chinot OL
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1413-27. PubMed ID: 23249106
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab and other targeted agents in the upfront treatment of glioblastoma.
Clarke JL
Semin Radiat Oncol; 2014 Oct; 24(4):273-8. PubMed ID: 25219812
[TBL] [Abstract][Full Text] [Related]
12. Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?
Seystahl K; Weller M
Expert Opin Investig Drugs; 2012 May; 21(5):605-17. PubMed ID: 22413865
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
